A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2019-12-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the median time to progression in participants with
hepatocellular carcinoma (HCC) when treated with LY2157299 as monotherapy and in combination
with sorafenib or ramucirumab.